Biohaven Pharmaceuticals

series-c-plus
series-c-plus
Stage
1
Investors

About

Biohaven Pharmaceuticals is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes therapies across neuroscience, immunology, obesity, and oncology. The company is known for migraine treatments including Nurtec ODT (rimegepant) and Zavzpret (zavegepant).

Explore Biohaven Pharmaceuticals's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.